{"id":4232,"date":"2026-02-25T08:25:53","date_gmt":"2026-02-25T07:25:53","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?page_id=4232"},"modified":"2026-02-25T08:25:53","modified_gmt":"2026-02-25T07:25:53","slug":"krebsimmuntherapien","status":"publish","type":"page","link":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/","title":{"rendered":"Cancer immunotherapy"},"content":{"rendered":"\n<p>The\nmedicines used in modern immunotherapy do not attack the tumour cells directly,\nbut instead direct the body\u2019s immune response towards them. This happens at\nlocations called immune checkpoints, which function as coordinating centres\nwithin the immune system that ensure that an immune reaction is inhibited and\nthat the system does not \u201coverreact\u201d and trigger an immune reaction against the\nindividual\u2019s own body. This is what happens in autoimmune diseases.<\/p>\n\n\n\n<p>Tumour\ncells can, however, exploit this inhibiting action at the immune checkpoints to\nblock a defensive reaction aimed at them. <\/p>\n\n\n\n<p>This\nis exactly the process targeted by immune checkpoint inhibitors. They release\nthe brake at the checkpoints, enabling the immune system to be reactivated and\nattack the tumour cells.&nbsp;The immune checkpoint inhibitors that have been\non the market since 2011 are achieving impressive results in certain\noncological indications such as advanced melanoma (skin cancer). <\/p>\n\n\n\n<p>The\nsuccess that has been achieved to date and current research findings in\nimmuno-oncology show that this new therapeutic concept can play a decisive role\nin the treatment of various cancers. For this reason, some of the innovative\nactive substances are already being used to treat different cancers or are\nbeing researched intensively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Challenges in authorisation\nand reimbursement<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>The\nrapid development of personalised medicine is increasing the number of\ntreatment options available for people with cancer, including combinations of\nchemotherapy and immunotherapy. However, some of these new medical products are\nnot yet authorised in Switzerland. This is particularly problematic if a\nmedicine is prescribed for an indication other than the one for which it has\nofficially been authorised by Swissmedic. This is known as off-label use (OLU),\nwhich is not automatically reimbursed by health insurers and is judged on a\ncase-by-case basis. The situation is similar for medicinal products that are\navailable in other countries but not authorised in Switzerland.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The medicines used in modern immunotherapy do not attack the tumour cells directly, but instead direct the body\u2019s immune response towards them. This happens at locations called immune checkpoints, which function as coordinating centres within the immune system that ensure that an immune reaction is inhibited and that the system does not \u201coverreact\u201d and trigger [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":4178,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-4232","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer immunotherapy - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer immunotherapy\" \/>\n<meta property=\"og:description\" content=\"The medicines used in modern immunotherapy do not attack the tumour cells directly, but instead direct the body\u2019s immune response towards them. This happens at locations called immune checkpoints, which function as coordinating centres within the immune system that ensure that an immune reaction is inhibited and that the system does not \u201coverreact\u201d and trigger [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/\",\"url\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/\",\"name\":\"Cancer immunotherapy - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"datePublished\":\"2026-02-25T07:25:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Our topics\",\"item\":\"https:\/\/www.interpharma.ch\/en\/themen\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Leader in research and development\",\"item\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"New approaches in research and treatment\",\"item\":\"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Cancer immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer immunotherapy - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/","og_locale":"en_US","og_type":"article","og_title":"Cancer immunotherapy","og_description":"The medicines used in modern immunotherapy do not attack the tumour cells directly, but instead direct the body\u2019s immune response towards them. This happens at locations called immune checkpoints, which function as coordinating centres within the immune system that ensure that an immune reaction is inhibited and that the system does not \u201coverreact\u201d and trigger [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/","og_site_name":"Interpharma","twitter_card":"summary_large_image","twitter_site":"@interpharma_ch","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/","url":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/","name":"Cancer immunotherapy - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"datePublished":"2026-02-25T07:25:53+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/krebsimmuntherapien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/en\/"},{"@type":"ListItem","position":2,"name":"Our topics","item":"https:\/\/www.interpharma.ch\/en\/themen\/"},{"@type":"ListItem","position":3,"name":"Leader in research and development","item":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/"},{"@type":"ListItem","position":4,"name":"New approaches in research and treatment","item":"https:\/\/www.interpharma.ch\/en\/themen\/fuhrend-in-forschung-entwicklung\/neue-forschungs-und-therapieansaetze\/"},{"@type":"ListItem","position":5,"name":"Cancer immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/pages\/4232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/comments?post=4232"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/pages\/4232\/revisions"}],"predecessor-version":[{"id":4233,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/pages\/4232\/revisions\/4233"}],"up":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/pages\/4178"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/en\/wp-json\/wp\/v2\/media?parent=4232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}